The prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen-matched red blood cells for thalassemia transfusions: a 10-year experience at a tertiary care hospital
STUDY DESIGN AND METHODS:
Thalassemia patients were recruited from a tertiary care hospital for 10 years from 2008 to 2017. The medical records of transfusion history were reviewed for red cell phenotype both of patients and donors, number of units transfused, and type of alloantibodies.
RESULTS: A total of 383 thalassemia patients were identified (178 males and 205 females). The frequency of RBC alloantibodies was 19 .3%. Some patients tested positive for more than one antibody type. Autoantibodies were detected in nine individuals. Anti-E (49 [39.5%]), anti-Mi a (24 [19.4%] ), and anti-c (19 [15.3%] ) were the most common antibodies detected. A high rate of alloimmunization was found in splenectomized patients. Risk of alloimmunization increased when more total units of blood had been transfused. A trend toward low alloimmunization rates was noted in the antigen-matched RBC group, where 3.5% (5/143) of patients were alloimmunized. Anti-E and anti-Mi a , which may be naturally occurring, were identified in this group. T halassemia is one of the most common inherited hemoglobinopathies in the world. It is caused by absent or reduced α-or β-globin chain synthesis. In Thailand, thalassemia is considered a major health problem; the average frequency of α-thalassemia in the population is 20% to 30%, β-thalassemia is 3% to 9%, and that of Hb E is 20% to 30%.
1 Hemoglobin E-β 0 thalassemia and homozygous β 0 thalassemia are the most common forms of chronic transfusion-dependent thalassemia with more than 700 patient deaths per year. 2 Patients with transfusion-dependent thalassemia require regular blood transfusions to maintain growth and development during childhood and to sustain a good quality of life during adulthood. 3, 4 However, repeated transfusion therapy can cause several complications that contribute to morbidity and mortality: transfusion-related adverse reactions, transfusion-transmitted allergic reactions, febrile nonhemolytic transfusion reactions, iron overload, and risk of development of red blood cell (RBC) alloantibodies and autoantibodies. Some alloantibodies may cause hemolytic transfusion reactions that are clinically significant. 3 In addition, RBC autoantibodies can result in hemolytic anemia and cause problems in crossmatching. 5 Thus the presence of these antibodies is not only a laboratory
From the 1 problem but can also delay the availability of compatible blood for a scheduled transfusion. Studies from several independent groups reported various frequencies of alloantibody formation in multiply transfused patients ranging from 5% to 30%. [6] [7] [8] [9] This variation in the reported rates may depend on the differences in genetic homogeneity of the donor and recipient populations, the study groups and transfusion management, and differences in the specificity and sensitivity of the reagents and test methods. 10, 11 Furthermore, the risks of alloimmunization against transfused RBC alloantigens are complex and also depend on the recipient's immune status and the immune modulatory effect of the transfused RBCs on the recipient. 3 Other risk factors reported are the age at initial transfusion, the number of units transfused, age, sex, genetic background, and environmental factors. 9, 12, 13 Extended RBC phenotyping and selection of blood negative for specific antigens reduces posttransfusion complications and allows for effective blood transfusion regimens to be achieved.
14 Although this process is widely used, its application is cumbersome and costly. Thailand currently has guidelines for prophylactic antigen matching for Rh (C, c, E, e) and Mi a antigens to prevent alloimmunization in thalassemia patients. 15 Others recommend to type for at least Rh (C, c, E, e) and Kell antigens because these account for most of the alloantibodies among Asians. 16 Several detailed transfusion guidelines for multiply transfused thalassemic patients have made recommendations such as use of a single donor to limit antigenic exposure and to improve antigen matching when selecting blood for transfusion. 16, 17 Following such recommendations, two studies reported alloimmunization rates of 3.7% and 8.3%. 16, 17 In our hospital, the policy since 2008 has been to match RBC antigens for at least C, c, E, e, and Mi a antigens, in addition to the routine ABO and RhD matching. Therefore, we now aim to 1) determine the prevalence of RBC alloantibodies and identify their types, 2) identify alloimmunization risk factors that may contribute to alloantibody formation in chronically transfused thalassemia patients, 3) assess the impact of antigenic exposure, and 4) assess the impact of an antigen-matched RBC policy. The goal is to improve transfusion strategy and reduce some of the transfusion-associated risks for thalassemia patients in Thailand. 
MATERIALS AND METHODS

Populations and recruitment
Statistical analysis
Data were managed and analyzed using Microsoft Excel 2013. All statistical analysis was performed using computer software GraphPad Prism. Qualitative data were expressed statistically in frequencies and percentages. Pearson χ 2 was used for comparing categorical variables. A p value <0.05 was considered statistically significant.
Study approval
The present study was approved by the Khon Kaen University Ethics Committee for Human Research (HE 611073).
RESULTS
Patient characteristics
Results from 383 thalassemia patients requiring regular blood transfusions were collected and analyzed ( 
Antibody screening and identification
Among the 383 thalassemia patients in this cohort (Fig. 1 anti-c in 19 (15.3%). In addition, specificity of 7 (5.6%) antibodies could not be determined.
Frequencies of alloantibodies in patients with thalassemia in the antigen-matched RBC program
This program focused on antigenic exposure and evaluation of antigen-matched RBC (C, c, E, e) and Mi a antigens.
Patients who had developed alloantibodies before the antigen-matched RBC program were excluded from further analysis. Also excluded were those lacking data for Rh phenotype or who were Rh-positive ( Fig. 2A) , and those lacking data for Mi a phenotype or who were Mi a -positive (Fig. 2B ).
After these exclusions, 218 patients were in the Rh-negative group ( Fig. 2A) and 125 in the Mi a antigen group (Fig. 2B ).
All of these subjects had the potential to develop alloantibodies when exposed to foreign antigens from donors. The antigen-matched RBC group included a total of 143 Rhmatched ( Fig. 2A ) and 24 Mi a -matched patients (Fig. 2B ). However, 5 of 143 (3.5%) in the Rh-matched group developed alloantibodies identified as type anti-E. Four of 75 patients in the antigen partially matched group became positive for anti-c and anti-E alloantibodies ( Table 3 ). All of those in the partially matched groups had received one or more alloantigenic exposures at least once during the study period (Supplementary Table 1 Table 3 ).
Seventy-one patients received Rh-antigen partially matched RBCs but did not develop RBC alloantibodies. Of these, 8 C-negative patients received C-positive transfusions with an average of 4 units each; 50 c-negative patients were exposed to c-positive blood (average 2.7 units each). The 47 E-negative patients had received E-positive blood (average 2.8 units each), and 8 e-negative patients were exposed to epositive blood (average 11.5 units each). The 98 patients who tested negative for Mi a had received Mi a -positive blood (average 7.3 units each) (Supplementary Table 2 ). All patients receiving RBC-incompatible transfusions had at least one follow-up test including antibody screening following antigen-positive exposures. The first follow-up investigation was between day 15 and day 30 after the transfusion event, all without evidence for the presence of antibodies. No antibody formation was observed in these patients (follow-up period >150 days), indicating nonresponder status.
Alloimmunization in relation to patients' data
Alloimmunization incidence was not influenced by the sex, age group, age at first transfusion, and ABO blood group (p > 0.05) ( Table 1) . However, risk of alloimmunization was significantly lower in patients who had received fewer than 20 units of blood transfused (10.6%) compared with those receiving more (p < 0.05) ( Table 1) . Alloimmunization frequency was significantly higher in splenectomized patients (34.5%) compared with nonsplenectomized patients (17.8%; p < 0.05). In addition, the mean number of RBC units transfused into splenectomized patients was significantly higher than for nonsplenectomized patients (109 vs. 54.8; p < 0.05). With regard to the 45 alloimmunized female subjects, we did not have reliable data on a previous or current pregnancy that might have contributed to antibody development. However, 33 of these 45 subjects were children and hence presumably had no history of pregnancy. All the antibodies detected in these patients would be transfusion related.
DISCUSSION
Ours is the first study to examine the prevalence, risk factors for alloimmunization, impact of antigenic exposure, and the clinical usefulness of antigen-matched RBC transfusions in Thai multi-transfused thalassemia patients. We demonstrated that the RBC alloimmunization rate in thalassemia patients was 19.3% with a rate of 4.5 antibodies per 100 units transfused. Previous estimates of alloimmunization rates among Asian thalassemia patients have ranged from 5.6% to 23.0%. 8, [18] [19] [20] [21] The reasons for these variations may be 1) differences between patient groups, 2) differences in genetic homogeneity of the donor-recipient population, 3) differences in routine screening practices, and 4) differences in sensitivity and specificity of reagents and testing methods.
18-21
The most common alloantibody in our 71 patients positive for these was anti-E (39.5%, a proportion similar to that in previous reports from China and northern India). 8, 22 Thirty-one of our 71 patients (43.7%) had anti-E alone, and Autoantibodies were detected in 9 of 74 patients (12.2%). Three of these had only autoantibodies, but six had both autoantibodies and alloantibodies. One patient had cold auto anti-I autoantibody. In some cases, anti-I autoantibody can cause chronic hemolytic anemia. 24 The incidence of alloantibodies in warm autoimmune hemolytic anemia is reportedly 11.3% in Chinese populations and 12% to 40% in whites. However, a study from Egypt did not find these autoantibodies. 9 The differences in these findings might be due to the splenectomy status of the patients and whether or not the patient received steroid treatment before each transfusion. However, the pathogenesis of RBC autoantibody formation after transfusion is not really understood. 25 When we analyzed the effect of the number of RBC units transfused, we found that alloimmunization frequency was significantly lower (p < 0.05) in patients who had received fewer than 20 units of blood transfused compared with patients who had received more (Table 1) . A similar finding was reported from Egyptian thalassemia patients. 26 In contrast, Abdelrazik and colleagues 9 reported no significant relationship between total number of RBC units transfused and alloimmunization in transfusion-dependent thalassemia patients in Egypt. Splenectomized patients in our study had a higher alloimmunization rate than nonsplenectomized patients (p < 0.05). Similar findings were reported in other studies. 3, 9, 17 However, some studies did not find an association between splenectomy and alloimmunization. [27] [28] [29] Interestingly, we observed that a high transfusion burden correlates with the need for splenectomy. Splenectomized patients in our study had more RBCs transfused than nonsplenectomized patients (p < 0.05). The high alloimmunization rate in the former group may simply reflect a higher RBC transfusion burden. The mechanism by which removal of the spleen increases the risk of RBC alloimmunization is not clear. It was hypothesized that postsplenectomy conformational changes in the RBC membrane enhance immunomodulation leading to an increased risk of RBC alloimmunization. 3, 30 In this study, the risk of alloimmunization was not influenced by sex, age group, age at initial transfusion, or ABO blood group (p > 0.05), similar to the findings of Shenoy et al 21 and other independent groups. 3, 6, 18, 31 In contrast, some studies reported sex as a risk factor for RBC Volume 59, January 2019 TRANSFUSION 181 alloimmunization in thalassemia patients but provided no explanation for this finding. 9,32 Pujani and colleagues and others 16, 33 also reported no significant difference in the alloimmunization rate between a group of patients who started transfusions at younger than 1 year of age and a group who started transfusions at older than 1 year. However, some studies showed a significant association between age and the risk of RBC alloimmunization, with the risk lowest among those patients who received their first transfusion at 24 months to younger than 6 years of age. 19, 34, 35 In particular, receiving a first transfusion before the age of 3 years was found to offer some protection against RBC alloimmunization in thalassemia patients, which supported the role of immune tolerance induced by the early exposure to repeated transfusion. 3 A trend toward low alloimmunization rates (5/143 patients [3.5%]) was noted in the antigen-matched (C, c, E, e) RBC group, which agrees with reports by other groups (2.8%-4.8%). 3, 16, 35 However, a moderately high rate of RBC alloimmunization (12.5%) was found in our patients who had received antigen-matched Mi a versus 3.0% in the antigen partially matched group. This difference might be due to the small number of subjects in the antigen-matched group. Moreover, the patients may have received RBC transfusions outside our hospital during the study. 
, respectively, had no detectable alloantibodies. In these cases, immediate-spin crossmatch RBC was implemented as a compatibility test. This practice may help reduce turnaround time, workload, and reagent costs, as well as serving as a more effective use of blood inventory. In addition, immediate-spin crossmatch is considered the most effective serologic method to recognize ABO incompatibility. 39 In our cohort, however, many patients who received one or more antigenic exposures did not form detectable RBC alloantibodies. Antibody-screening tests of patients following antigen-positive exposures should be done to identify nonresponders. In nonresponders, the total length of follow-up was considered as the interval between the first exposure and the last antibody-screening test. All patients in our study receiving partially matched RBCs were followed up for more than 150 days, and all remained antibody-negative. At present, it remains unclear whether "nonresponders" who do not develop RBC alloantibodies are tolerant of all or some of the transfused antigens, or whether their immune systems are simply ignorant of the antigen exposures. 40 Several studies of responder and nonresponder patients have focused on general descriptions of immune-cell subsets. 41, 42 Schonewille and colleagues 43 proposed that some recipient HLAs such as HLA-DRB1*15 may be markers of hyperresponders. In addition, a current study by Tian and colleagues 44 revealed that HLA-DRB1*09:01 is associated with anti-E immunization. In this regard, a future study of nonresponsiveness may be as useful as understanding responsiveness. This study had several limitations. Pregnancy as a potential immunizing event could not be reliably excluded because information on pregnancy status was not available in our blood transfusion information system. We also did not have reliable data on the timing of splenectomy. Thus it remains unclear whether alloimmunization occurred before or after the splenectomy.
In conclusion, we discussed the prevalence of RBC alloantibodies, risk factors for alloimmunization, the impact of antigenic exposure, and the evaluation of antigen-matched RBC transfusions for thalassemia patients in Thailand. We conclude first that the alloimmunization rate in Thai thalassemia patients who are on repeated transfusion therapy is high. The most common alloantibodies were anti-E followed by anti-Mi a and anti-c. Second, provision of at least Rh and Mi a antigen-matched leukocyte-reduced RBC transfusion may minimize the risk of the formation of RBC alloantibodies and improve the efficiency of transfusion in thalassemia patients.
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